Monoclonal Antibody Development Targeting CD137-CD137L for Autoimmune Diseases

Agonizing cluster of differentiation 137 (CD137) can reduce the pathogenic autoantibodies and lymphocytes and ameliorate clinical manifestation of systemic lupus erythematosus (SLE) in animal models. Therefore, the development of new drugs for autoimmune diseases focuses on the research of the CD137-CD137 ligand (L). Creative Biolabs offers the monoclonal antibody (mAb) development services targeting CD137-CD137L to promote the treatment of autoimmune diseases (ADs). Our team has extensive experience in mAb development. Our operational grit and scientific background help you get milestone success.

Short Introduction of CD137-CD137L

CD137 belongs to TNF superfamily member 9 (TNFSF9). It is a potent costimulatory receptor molecule that is mainly expressed on stimulated T cells and natural killer (NK) T cells. In both the murine systems and humans, cognate interaction between CD137 and CD137L on activated T cells and B cells, respectively, leads to proliferation and differentiation of both interacting cells and results in substantial Ig production. Indeed, bidirectional signaling ensues in the T and B cells or antigen-presenting cell (APC) during CD137-CD137L interaction.

Fig.1 CD137/CD137L signaling in immune cells. (Wong, 2020)

CD137-CD137L and Autoimmune Diseases (ADs)

Scientists have revealed that loss of CD137 can worsen lupus and increase mortality. When mice accept a treatment with agonistic anti-CD137 antibodies, the disease in murine lupus models alleviates. In another study, scientists investigated immune modulations and the subsequent effects on renal, cutaneous, and cerebral manifestations in a murine lupus model with CD137L deletion. They found that the absence of CD137L aggravates glomerulonephritis and dermatitis. The next analysis showed that loss of CD137L results in less inflammation and demyelination in the cerebral cortex, hippocampus, thalamus, and hypothalamus. So, scientists have a conclusion that the lack of CD137L protects against brain damage in the experimental autoimmune encephalomyelitis model.

mAb Development of CD137-CD137L

Based on the study of ADs and mAb, Creative Biolabs has built up a wide spectrum of mAb development services, such as mAb targeting CD137-CD137L to promote the treatment of ADs. At Creative Biolabs' mAb development platform, we can provide conventional protein and peptide antigens to produce antigen-specific monoclonal antibody with high affinity and low cross reactivity. Most importantly, we can customize special monoclonal antibody discovery services to meet any specific demands.

Fig.2 Soluble CD137 in physiological condition and autoimmunity. (Wong, 2020)

With industry-leading expertise and state-of-the-art equipment, Creative Biolabs provides accurate and effective antibody development solutions for researchers all over the world. We will work with you at all stages of CD137-CD137L mAb development process from the initiation design of your project to the large-scale production. If you are interested in our services, please contact us.

Reference

1. Wong, H. Y.; Schwarz, H. CD137/CD137 ligand signaling regulates the immune balance: A potential target for novel immunotherapy of autoimmune diseases. Journal of Autoimmunity. 2020, 112: 102499.

For Research Use Only | Not For Clinical Use